Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05236114 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GEMINI-NSCLC: NSCLC Biomarker Study

StatusRecruiting
PhaseNot specified
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 57 to 58v20
  2. Site contacts updated at 1 of 57 sitesv19
  3. Study sites: 55 to 57v18
  4. Study sites: 53 to 55v17
  5. Study sites: 49 to 53v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 47 to 49v15
  2. Site contacts updated at 1 of 47 sitesv14
  3. Study sites: 42 to 47v13
  4. Study sites: 40 to 42v12
  5. Primary completion date: Jun 2025 to Jun 2029 Primary endpoints revised (2) · Enrollment target: 813 to 1200 · Study sites: 38 to 40 · 4 morev11 Show 7 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 813 to 1200
    • Study sites: 38 to 40
    • Completion date: Feb 2027 to Jun 2029
    • Eligibility criteria expanded, about 664 words
    • Secondary endpoints: 3 to 10
    • Publications: 46 to 61

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 31 to 38v10
  7. Re-verified, no change to tracked fieldsv9
  8. Primary completion date: Feb 2024 to Jun 2025 Study sites: 19 to 31v8 Show 1 more changeShow less
    • Study sites: 19 to 31
  9. Study sites: 16 to 19v7
  10. Re-verified, no change to tracked fieldsv6
  11. Study sites: 9 to 16v5
  12. Enrollment target: 338 to 813 Study sites: 4 to 9 · Eligibility criteria expanded, about 27 words · Publications: 39 to 46 · 2 morev4 Show 5 more changesShow less
    • Study sites: 4 to 9
    • Eligibility criteria expanded, about 27 words
    • Publications: 39 to 46
    • Study title shortened, about 12 words
    • Collaborators expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  13. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Start date changed from estimate of May 2022 to Jun 22, 2022v3 Show 2 more changesShow less
    • Study sites: 0 to 4
    • Start date changed from estimate of May 2022 to Jun 22, 2022
  14. Start date: Feb 2022 to May 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Trial Details
NCT Number NCT05236114
Lead Sponsor Tempus AI
Collaborators: AstraZeneca
Conditions Non-Small Cell Lung Cancer
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov